OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

t
thanks for your explanation.full of holes.
so, you averaging down then?
stay lucky and have a nice christmas.
regards
jkd

JKDI have answered all your accusationsall in print for any referenceeven post numbers... please post what part of my answers were full of holes

Most posters will clearly see what an arse you have made of yourselfas usual!!! your post was full of mistakesno research as usual!!!and I get no apologyas usual!!!now do what you normally do when you are wrong..breeze away like the mistral winds

t
if you cant see them and need me to point them out then it is little wonder you keep falling into them.
regards
jkd

JKDI have been completely honest as alwaysif you refuse to point out my dishonestyyou rather lose the battle

I swear you are bonkers!

Can any JKD fan point out what he is on about.Im struggling!

For me it is a simple case that small biotech companies that I know of are being hammered in the market for the simple reason that they are loss making and therefore need funds and with the market as it is, it believes the funds may not be forthcoming.

When the sp fell a year or two ago the company came out and said they didn't understand the drop as they still had funds for that the next two years. It made no difference to the market and as we know the sp has stayed around 10p for as long as I care to remember. The company may well have believed that over the past year the sp would have recovered somewhat and then they would tap the market for the said funds. This just hasn't happened so they have got in now rather than wait 6 months when the sp might have been 5p anyway and the fundraising would then have been at 2-3p.

I guess at the end of the day, either the market will see these companies in a better light or they will go bust unless of course they come up with some innovative deal that turns the sp around.

Only my take of course.

Dealerthat is a reasonable take on the situationbut with 78 staff to paythen to spend 5.4m on a manufacturing facilitywhen you might not have a business in two yearsa further 8.2m will go on developing a possible treatment for Parkinson's ProSavinthat leaves diddly squator 4.8m after costs to fund the business
Two scenarios in my opinion. A bod's as cranky as JKD or developing the business on privileged information

After talking to the company I backed my hunch yesterday!

hunches pay for lunches.
what about dinner or the mortgage?
i truly hope this company succeeds.and i dont care about t making a mint, i hope he does,just wish he would be a little more honest about it,thats all.
just my opinion of course.
regards
jkd

JKDI will ask you one more timeput up or shut up.where have I been dishonest?
Posted my saleposted my losswrote to the company and posted the complete replyposted my reasons for re-investing.asked people to dyorposted that in my opinion this was a total puntand I must be Crackers!
Now my opinion isyour opinion stinksI could easily lose all this investmentand I am all ready down from my lastmy hunch is that something stinksand I have backed that judgementpleaseno one invest on my hunchand JKDresearch before you accuse me!

ProSavin Phase I/II Update
Share this article

TIDMOXB

RNS Number : 3956Y

Oxford Biomedica PLC

22 December 2010

OXFORD BIOMEDICA ANNOUNCES UPDATE ON PROSAVIN(R) PHASE I/II STUDY IN PARKINSON'S DISEASE

-- Encouraging third cohort results using enhanced administration technique --

-- Data Monitoring Committee supports progression to 5x dose in Q1 2011 --

Oxford, UK - 22 December 2010: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD). Three-month data from the third patient cohort show that ProSavin(R) continues to be safe and well-tolerated following treatment with a 2x dose using an enhanced administration technique developed by the Company. The enhanced technique has been shown to reduce the surgical delivery time, will facilitate higher dosing and has the potential to provide better reproducibility of administration as study centres expand.

By way of background, the current Phase I/II study is designed to assess the safety, efficacy and dose evaluation of ProSavin(R) in patients with mid-stage PD who are experiencing reduced benefit on L-DOPA "equivalent" therapy. To date, nine patients have been treated in cohorts of three. In June 2010, Oxford BioMedica reported 24-month results from the first cohort which received a 1x dose of ProSavin(R), in addition to 12-month results from the second cohort which received a 2x dose of ProSavin(R). Motor function is assessed according to the Unified Parkinson's Disease Rating Score (UPDRS) in patients' "OFF" state (i.e. after withdrawal of PD medication). Quality of life is assessed based on a standard measure of clinical benefit using a patient questionnaire known as PDQ-39. Patients from the third cohort who received a 2x dose of ProSavin(R) using the Company's enhanced administration technique have now reached their three-month assessment:

Highlights of third cohort at three months (2x dose, enhanced administration)

-- Favourable safety profile with no serious adverse events related to ProSavin(R) or the enhanced administration technique;

-- Average motor function improvement of 26%, consistent with 28% improvement using the old administration technique at the 2x dose, with a maximum of 52% improvement in one patient;

-- All three patients show improvements in at least one indicator of clinical benefit; and

-- Surgery delivery time for the 2x dose reduced by approximately 50%.

Highlights across all treatment cohorts (total of nine patients)

-- Patient diary data show an increase in "ON" time (when PD symptoms are not present) in all three cohorts;

-- L-DOPA "equivalent" therapy has either reduced or remained stable in all three cohorts, in what is usually a progressively degenerative disease requiring an increase in dose;

-- Quality of life has either improved or remained stable in all three cohorts, again where it would usually be expected to worsen; and

-- ProSavin(R) continues to have a favourable safety profile 30 months post-treatment (1x dose) and 18 months post-treatment (2x dose);

- As previously reported, 1x dose data showed average motor function improvement of 20% at 24-months (with a maximum of 30% in one patient) and 2x dose data showed average motor function improvement of 29% at 12-months (with a maximum of 56% in one patient).

The study's independent Data Monitoring Committee (DMC) has reviewed the data and supports the Company's proposal to proceed to a 5x dose, facilitated by the enhanced administration technique, in a six-patient cohort. Importantly, the 5x human dose is the allometrically-scaled equivalent (i.e. a dose that is scaled for the difference in brain size between humans and the pre-clinical model) to the highly efficacious pre-clinical dose published in Jarraya et al. Sci Transl Med. 2009 Oct 14;1(2). The DMC also gave its approval to open the second site in the UK at Addenbrookes Hospital, Cambridge, with Dr Roger Barker as Principal Investigator, which will recruit some of the six patients into the 5x dose cohort.

Oxford BioMedica plans to initiate treatment of the 5x dose cohort in Q1 2011. To date, nine patients have been treated at the Henri Mondor Hospital, Paris, with Professor Stephane Palfi as Principal Investigator. The first patient in the 5x dose cohort will be treated in Paris, one month after which subsequent patients can be treated in parallel at both sites which is expected to increase the rate of recruitment and treatment. Results from the first three patients in the 5x dose cohort are expected in mid-2011. Depending on the efficacy seen with the 5x dose, a Phase II trial of ProSavin(R) could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programme.

Commenting on the nine patients treated, Professor Stephane Palfi said: "The safety of the new administration method and the continued safety profile of ProSavin(R) are both very favourable and the data from the earlier cohorts provide encouraging signs of long-term benefit. We can now be confident to administer ProSavin(R) at a dose which showed the best benefit in a severe pre-clinical model of Parkinson's disease."

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "This first-in-man Phase I/II study is an appropriately cautious approach to a potentially revolutionary treatment for Parkinson's disease. With the excellent safety profile and sustained, positive signs of clinical benefit we have seen at the lower doses, we are confident that progressing ProSavin(R) to the 5x dose could further enhance efficacy and therefore significantly increase the product's value. We are making the necessary preparations to advance ProSavin(R) into Phase II development as rapidly as possible including site expansion, regulatory guidance and manufacturing and we look forward to continuing our discussions with potential partners as we generate more data from this increasingly valuable asset."

Im know medical expertbut these points seem to be crucial and exciting

-- Encouraging third cohort results using enhanced administration technique --

-- Data Monitoring Committee supports progression to 5x dose in Q1 2011 --


-- Quality of life has either improved or remained stable in all three cohorts, again where it would usually be expected to worsen; and

-- ProSavin(R) continues to have a favourable safety profile 30 months post-treatment (1x dose) and 18 months post-treatment (2x dose);



First bit of good news

This announcement seems to be a good way of insuring complete take up of Open Offer well prior to deadline. I remain optimistic for this small innovative British Company - 2011 will it seems see them hit the headlines for good reasons.

Posted by a guy on another BBI have copy and paste this up as it echos my view exactlyalthough OXB is still a risky puntthe current price could make it a very nice earner:-


"Well, we are where we are!

I havent posted anything since the placing 13-12-10, I didnt want to post anything until I knew what today RNS had in it.

I thought the Placing was going to happen from talking to the company (just inference not a direct statement).
But I didnt think it was going to happen until the New Year and I would have expected them to at least tried to raise the share price by any means available eg concerted PR campaign etc.
Some I know (on this board) got out just before the dirty deed was done, and to them I say well done, I would have myself if Id read it correctly, but sadly I was fully loaded.

Although I have a portfolio of shares and other investments I have over the years developed a far too heavy weighting towards Biomedica shares, but for the following reasons (God help me) Im going to take up all my options AND a big chuck of the additional offering (subject to share price immediately before committing):-

Ive had lengthy discussion with some of the directors and Lara (who deserves a medal she seems to be contacting everyone).
I do believe them when they say that they had gone over and over the timing of the placing in the end it got taken a little out of their hands but I dont think it was far away from happening anyway. They firmly believe that the market would not have taken them seriously next Aug/Sept/Oct when they would have to have done it anyway. They also firmly believe that negotiating the Prosavin deal next summer would have been made extremely difficult with only 5 to 6 months money left.
I personally was never told that there was a Prosavin deal on table.
So the poultry amount raised was really out of their hands (apart from perhaps the above mentioned PR campaign).

I mentioned above todays RNS, well my biggest fear was delay (however, fear of slippage will always be with us), I was concerned that the placing timing might have been because the 2X infusion result nowhere near as good as the injected method. I also feared that go ahead for 5X infusion would get delayed. This, if it was 4 to 5 months (which is not unheard of for OXB), would seriously have depleted most of the gains of the placement.
So todays RNS has settled those immediate fears, I have also discussed these results and they havent given any signs that there are any worries for us once the detail is revealed.

Next is the biggest shock the manufacturing facility, which I really couldnt work out. As weve all thought and read on here this seems like a massive mistake when youre strapped for cash. Having spoken to Biomedica the biggest clinchers for me are (least import first) 1) We get more of the Prosavin action 2) Sanofi want OXB to mange the optical manufacturing 3) it will guarantee manufacturing and stop delays AND most importantly 4) It makes economic sense !! I hadnt realised the manufacturing costs for the Lentivector products are so high, it will pay for itself very quickly.

Sanofi Optical products. They talk about this as if it a now a given and just a formality. I think this is foolish but you cant get more positive than that.

Trovax. I still believe this could be massive, and Im glad that they think so also. Apparently Provenge has increased dramatically the interest in Trovax."

Have only skimmed through some of the posts, but any would be investor should remember that only a small percentage of development drugs reach commercial sale, less than 10% springs to mind. Sanofi hasn't even reached Stage 3 yet so an awful long way to go. I doubt OXB have sufficient funds to see it through and will have to come back to the Market for more cash.

The returns on Bios can be remarkable but so few actually reach commerciality, most crash and burn, AZM a most recent example.

Peteronly a small percentage of development drugs reach commercial sale, less than 10% springs to mind

I cannot find that statistic at any of these levelsPhase 1 trials Phase 2 trials Phase 3 trials Phase 3 Randomisationalso you say:-


Sanofi hasn't even reached Stage 3 yet so an awful long way to go

Please expand on that statement...it doesnt make sense...

FWIW if they were being "Taken Out" then the same leaking mechanism would have started to ramp up the sp. That they are committed to selling shares (subject s-app), means there is no news for the "forseeable future".

Furthermore I don't see a BigBio taking them out too soon - they will have plenty of opp. in the past....as soon as Sanofi waved goodbye, leaving a fat cheque (for example).
The truth is OXB isn't going anywhere fast; but that's not the reason I'm investing - I think it is the best prospect at 5p I can find.

I'll agree they are taking their time about it, but they report RNS as and when - - - I get the impressioopn this is an honest Research Bio.
PS If tabasco sold out weeks ago, what's the problem? - although I'll admit I thought it was within hours of the Ann. but maybe that's "not reading" his words, rather scanning for the sense and wrongly concluding I thought he was lucky (shall we say?).. Look at the sp fall and it seems V.many had advance warning - something that the City fails to fix . . . . could it be there are too many at it? I missed the Newspaper comment entirely.
I'm posting the cheque today . . . . deadline is 1st wk in Jan11.
Good luck, I hope to show a sm profit soon- reads: I'm av. dn..

PS Yes that figure 90% fail...read are not funded through to commercialisation. The costs ramp-up going thro' Phase Trials, so weeding out early is Good....in the case of OXB they have some newer products, but somehow have failed to get something to sell. I liked PTI(Protherics) for that reason...a regular income. "Research" can become a purpose in its own right, whereas investors want Products flying off the shelves, even if it's nail-cure.
The biggest worry is that someone else finds an equally-good cure, then the Q is "Is it worth the risk" = to topple the early-bird?

Apologies - a mistype, should have read:

Prosavin does not appear to have reached Phase 2:

"Depending on the efficacy seen with the 5x dose, a Phase II trial of ProSavin(R) could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programme"

Full Explanation of Clinical Trials

The 90% failure of drugs not reaching commercial proportions was something I stumbled upon whilst invested in a company called CeNeS (which turned out to be an unmitigated disaster). CeNeS did actually reach Phase 3 successfully, but having retunred to the market so many times for additional funds, they ran out of options and were eventually absorbed by a major. It costs somewhere in the region of $1Billion from original concept to appearance on the shelves in your local chemist, which explains why so many of these R&D minnows disappear or are taken over. In the meantime, your original investment is diluted so many times it becomes pratically worthless.

(And if you're wondering why I have responded Tabby, as it is the season of goodwill, you've become unsquleched - Happy Xmas).

Peterthanks for the replyand a merry xmas to you and your family

As I have said on several occasionmy re-investment in oxb is a complete punt whilst riskyI believe the upside from this point is favourite what clinched it for me.. was Sanofi and the manufacturing facilitythis seems madness when buying time and fighting for your lifebut

What if Sanofi had already had a quite word and gave reassurances?what if a deal is already done?We know Sanofi want OXB to manage the optical manufacturingthis ties in with Oxb confidence in only setting a few mil aside to fund the business
Dont forget this additional cash will fund the purchase of the manufacturing facility beyond Sanofi Aventiss option to license one or more of the ocular programmesthis is a done dealand would trigger double-digit $million payments
That is what we know.how about what we dont know?

Sorry Hangonjust read your postcould the first leaking mechanism have been to deter pis from taking up the offer?Would that leave Sanofi doing oxb a big favour and buying a shed load?if Sanofi has already offered oxb and the bods a healthy futuredo you think the bod would worry if the SP was low when an offer for the company came in?no more worries for the bodpis ecstatic with 25p or moreand Sanofi having it off on the cheapeveryones a winner Rodney!

I hope the bod would think their collective efforts are worth more than 25p
In general, but not set in stone:
I will only buy Plus below 25p, AIM below 50p and FTSE below 1 (other than FTSE100, which have a dividend history, etc.)
Indeed Plus is now off my list, their business model is "self,self" with little regard IMHO to we investors - just look at the rag-bag (can I say that?) of co's that are attracted there. I find making a profit very unlikely.(rant over!).
Now, OXB is fully-listed, ISA-able and presumably fully compliant with FTSE Rules, etc. This is not a toy pharma ( if their "Future" is to believed). Even 50p would not reflect their future value, but probably close "now" with much to prove.
An example of a Toy-Pharma is PY- (you can guess), with their SP graph, Boo-Hoo = lost a lot I did.BTW I read in the FT, the "reason" for OXB fundraising was to exert more "clout" when negotiating a Partner-Deal in 2011 - This makes sense, esp. as the UK"ecomomy" doesn't appear to be turning round too quickly. i.e. do it "now" - it's just a pity PI's have been shafted as usual, in the short-term, anyway.

+What really amazes me is the FTSE100-level is nearly 6000. Wow and BP isn't paying a Divi and many Retailer may have (Snow) sob-stories to tell- and industry also, I suspect (Blame it on the Weather!)....